

## Morgan Stanley Investment Funds

# US Dollar Corporate Bond Fund

GLOBAL FIXED INCOME TEAM | MONTHLY COMMENTARY | 31 JANUARY 2021

### Performance Review

In the one month period ending 31 January 2021, the Fund's Z shares returned -14.1% (net of fees)<sup>1</sup>, while the benchmark returned -1.28%.

Over the month, the portfolio's overall investment grade positioning detracted from returns, driven primarily by positioning in non-financials. Small overweights to retailers, food & beverage, electric, and media & entertainment detracted from returns. Underweight positioning in consumer non-cyclicals, specifically health care, also negatively impacted performance over the month.

Within financials, an overweight to banking and insurance also detracted. This was partially offset by small off-index allocations to high yield, convertibles and emerging market corporates, which were additive.

### Market Review

In anticipation of a strong rebound in growth by the end of 2021, government bond yields across the developed markets moved higher in January, despite the emergence of new, more contagious COVID-19 strains. The "reflation trade" continued to pick up momentum in the markets, as inflation breakevens hit multi-year highs. Following weakness in December, the U.S. dollar strengthened against a basket of currencies amid equity market volatility in January.

In the U.S., the Federal Open Market Committee (FOMC) kept monetary policy unchanged at its January meeting and reinforced its intention to keep policy easy for a long time. Officials also dispelled concerns about tapering too soon lest it may tighten financial conditions prematurely. The Federal Reserve (Fed) also discussed inflation, stating that while inflation is a risk, it's not a "primary" risk. The Fed expects the higher inflation levels that may be seen this year to be transitory. The Fed intends to maintain the current pace of \$120 billion of purchases per month until "substantial further progress" has been made on employment and inflation goals. From a fiscal perspective, newly inaugurated President Joe Biden introduced a new \$1.9 trillion stimulus program, in addition to the \$900 billion stimulus that was agreed in late December. "America's Rescue Plan" includes direct payments to individuals, assistance for small businesses, state and local government aid, and vaccine rollout funding. Data over the month was mixed, as PMIs and housing market data suggested signs of strength, while gross domestic product (GDP) and labor market data pointed to some of the remaining weaknesses in the economy.

In Europe, strict lockdowns and restrictions continued to wreak havoc and threaten the region's recovery, coupled with a slower-than-expected vaccine rollout. After expanding its stimulus program in December, the European Central Bank (ECB) did not make any changes to policy at its January meeting. ECB President Christine Lagarde emphasized that "ample monetary stimulus remains essential" and that the bank remains ready to act if deemed necessary. In its meeting minutes, ECB members disclosed that they are closely watching the appreciation in the euro against the U.S. dollar, highlighting that its appreciation could be a contributor to subdued inflation in the euro area. Lagarde also stated inflation is likely to face downward pressure with weaker demand and lower wage pressures.

In the U.K., although national lockdown measures remained intact, vaccine rollouts have been quite efficient thus far, with over 13% of the population receiving the vaccine to date. Chancellor Rishi Sunak announced a £4.6 billion financial support package targeted at struggling U.K. companies. The package will stay in effect until at least February 15, 2021. Despite this, economic data was weak over the month.

At its January meeting, the Bank of Japan (BoJ) left rates on hold at -0.1% and also maintained its target for the 10-year bond yield at approximately 0%. The BoJ stated that it will continue to target 2% inflation with its current policy and asset buying framework, and does not foresee reducing or eliminating any stimulus or support for the foreseeable future. The central bank did upgrade its economic forecast for the next fiscal year, moving its GDP forecast higher by 0.3% and also raising its core

<sup>1</sup> Source: Morgan Stanley Investment Management Limited. Data as of 31 January 2021.

inflation expectations. However, central bank officials did caveat their upgraded forecasts, stating that there are escalating risks to the outlook as emergency coronavirus measures could derail the country's recovery.

#### Investment Grade:

After a strong end to 2020, risk assets took a breather to begin 2021. Risk-free yields were higher in January, with the U.S. 10-year closing 15 basis points (bps) higher at 1.07%, while core European yields also rose. Equity volatility increased in January, and the major indices ended the month slightly lower. Like the markets, the news flow was mixed as well. The Democratic Party secured control of Congress with victories in the two Georgia runoff elections. This opened the door for another large stimulus package, which would be a pro-cyclical shot in the arm for the U.S. economy. Unfortunately, the fiscal boost may be sorely needed, as new COVID-19 variants and logistical questions over the vaccine rollout have raised the risk of longer lockdowns. In the end, credit markets didn't know which way to go and ended the month nearly unchanged.

The Bloomberg Barclays U.S. Corporate Index (U.S. investment grade index) rallied to an intra-month low of 92 bps over government bonds, but couldn't hold the gains and closed January unchanged at 96 bps. As a result, the index generated total returns of -1.28%. Financials widened by 1 bp, underperforming non-financials, which were flat. Within non-financials, BBB rated names outperformed higher-rated securities by a small margin. At the industry level there was some subtle variation in performance, with most sectors +/-3 bps for the month. In terms of excess returns versus government bonds, the U.S. investment grade index generated a marginally positive excess return of 0.03%. Performance of European investment grade was very similar to the U.S. market. The Bloomberg Barclays Euro-Aggregate Corporate Index (European investment grade index) closed unchanged at 92 bps over government bonds and generated total returns of -0.12%. Financials closed 1 bp wider, underperforming non-financials, which were unchanged. In terms of excess returns versus government bonds, the European investment grade index generated a marginally positive excess return of 0.01%.

On the supply front, roughly \$123 billion of new investment grade bonds were issued in January, down 5% year-over-year and 7% below past January averages. The 10 largest deals that came to market accounted for 45% of the total issuance for the month, of which two deals were related to acquisition financing. Merger and acquisition-related debt issuance was \$14 billion in January, and we expect this trend to remain prevalent throughout the year as issuers take advantage of historically low funding costs. Supply from the large U.S. banks, a common occurrence in January, came in a little lower than expected, with one large name staying out of the market for the time being. While gross supply was down, signaling that some supply may have been pulled forward into 2020 given the low yields and tight credit spreads in the fourth quarter, we expect supply to pick up once earnings season is behind us. Future supply is expected to be key to market sentiment, with a healthy calendar expected post-fourth-quarter reporting in order to lock in low yields.

#### Portfolio Activity

While macro and credit fundamentals are pointed in the right direction, valuations are far from exciting. We remain long risk as we believe technicals should push spreads tighter, but are cognizant that the days of strong total returns are likely behind us. As a result, we have continued to move up in quality and liquidity and are carefully considering sector weightings to see where rotation at tight valuations makes most sense.

#### Strategy and Outlook

Despite the market's lackluster performance to start the year, we continue to see a constructive backdrop for investment grade credit. In our base case, credit spreads remain supported by the vaccine rollout and continued positive support from monetary and fiscal policy, which will make 2021 a year of reflation. Earnings season has just begun, but fourth quarter results from the banks were strong and highlighted the resiliency of the U.S. consumer. We expect credit spreads to move tighter in the short to medium term given this backdrop. A steeper U.S. yield curve and attractive hedging costs for non-U.S. dollar investors should also help bring investors into the market. There are risks of volatility, but we believe any downside is limited by expectations that vaccines will be increasingly deployed in the next few months. With such a supportive backdrop, it is possible that credit spreads overshoot fair value during the first half of 2021, though the outperformance should be limited with spreads already tight versus the long-term average. We expect spreads to give back these gains later in 2021 as tight valuations encounter renewed shareholder-friendly activity, increasing merger and acquisition activity and questions about policy expectations for 2022.

**For further information, please contact your Morgan Stanley Investment Management representative.**

#### FUND FACTS

##### Launch date

20 May 2016

##### Base currency

U.S. dollars

##### Index

Bloomberg Barclays U.S. Corporate Index

## 12 Month Performance Periods to Latest Month End (%)

	JANUARY '20 - JANUARY '21	JANUARY '19 - JANUARY '20	JANUARY '18 - JANUARY '19	JANUARY '17 - JANUARY '18	JANUARY '16 - JANUARY '17
MS INVF US Dollar Corporate Bond Fund - Z Shares	6.80	16.23	-0.15	4.95	--
Bloomberg Barclays U.S. Corporate Index	5.99	14.53	0.75	5.08	--

**Past performance is not a reliable indicator of future results.** Returns may increase or decrease as a result of currency fluctuations. All performance data is calculated NAV to NAV, net of fees, and does not take account of commissions and costs incurred on the issue and redemption of units. The sources for all performance and Index data is Morgan Stanley Investment Management. **Please visit our website [www.morganstanley.com/im](http://www.morganstanley.com/im) to see the latest performance returns for the fund's other share classes.**

## Share Class Z Risk and Reward Profile

Lower Risk

Higher Risk



Potentially Lower Rewards

Potentially Higher Rewards

The risk and reward category shown is based on historic data.

- Historic figures are only a guide and may not be a reliable indicator of what may happen in the future.
- As such this category may change in the future.
- The higher the category, the greater the potential reward, but also the greater the risk of losing the investment. Category 1 does not indicate a risk free investment.
- The fund is in this category because it invests in fixed income securities and the fund's simulated and/or realised return has experienced medium rises and falls historically.
- The fund may be impacted by movements in the exchange rates between the fund's currency and the currencies of the fund's investments.

This rating does not take into account other risk factors which should be considered before investing, these include:

- The value of bonds are likely to decrease if interest rates rise and vice versa.
- The value of financial derivative instruments are highly sensitive and may result in losses in excess of the amount invested by the Sub-Fund.

- Issuers may not be able to repay their debts, if this happens the value of your investment will decrease. This risk is higher where the fund invests in a bond with a lower credit rating.
- The fund relies on other parties to fulfill certain services, investments or transactions. If these parties become insolvent, it may expose the fund to financial loss.
- There may be an insufficient number of buyers or sellers which may affect the funds ability to buy or sell securities.
- Past performance is not a reliable indicator of future results. Returns may increase or decrease as a result of currency fluctuations. The value of investments and the income from them can go down as well as up and investors may lose all or a substantial portion of his or her investment.
- The value of the investments and the income from them will vary and there can be no assurance that the Fund will achieve its investment objectives.
- Investments may be in a variety of currencies and therefore changes in rates of exchange between currencies may cause the value of investments to decrease or increase. Furthermore, the value of investments may be adversely affected by fluctuations in exchange rates between the investor's reference currency and the base currency of the investments.

Please refer to the Prospectus for full risk disclosures. All data as of 31 January 2021 and subject to change daily.

## INDEX INFORMATION

The **Bloomberg Barclays U.S. Corporate Index** is a broad-based benchmark that measures the investment grade, fixed-rate, taxable, corporate bond market.

The **Bloomberg Barclays Euro-Aggregate Corporates bond index** is a rules based benchmark measuring investment grade, EUR denominated, fixed rate, and corporate only. Only bonds with a maturity of 1 year and above are eligible.

## DISTRIBUTION

This communication is only intended for and will only be distributed to persons resident in jurisdictions where such distribution or availability would not be contrary to local laws or regulations. In particular, the Shares are not for distribution to US persons.

**Ireland:** MSIM Fund Management (Ireland) Limited. Registered Office: The Observatory, 7-11 Sir John Rogerson's Quay, Dublin 2, D02 VC42, Ireland. Registered in Ireland as a private company limited by shares under company number

616661. MSIM Fund Management (Ireland) Limited is regulated by the Central Bank of Ireland. **United Kingdom:** Morgan Stanley Investment Management Limited is authorised and regulated by the Financial Conduct Authority. Registered in England. Registered No. 1981121. Registered Office: 25 Cabot Square, Canary Wharf, London E14 4QA, authorised and regulated by the Financial Conduct Authority. **Dubai:** Morgan Stanley Investment Management Limited (Representative Office, Unit Precinct 3-7th Floor-Unit 701 and 702, Level 7, Gate Precinct Building 3, Dubai International Financial Centre, Dubai, 506501, United Arab Emirates. Telephone: +97 (0)14 709 7158). **Germany:** MSIM Fund Management (Ireland) Limited Niederlassung Deutschland, Grosse Gallusstrasse 18, 60312 Frankfurt am Main, Germany (Gattung: Zweigniederlassung (FDI) gem. § 53b KWG). **Italy:** MSIM Fund Management (Ireland) Limited, Milan Branch (Sede Secondaria di Milano) is a branch of MSIM Fund Management (Ireland) Limited, a company registered in Ireland, regulated by the Central Bank of Ireland and whose registered office is at The Observatory, 7-11 Sir John Rogerson's Quay, Dublin 2, D02 VC42, Ireland.

MSIM Fund Management (Ireland) Limited Milan Branch (Sede Secondaria di Milano) with seat in Palazzo Serbelloni Corso Venezia, 16 20121 Milano, Italy, is registered in Italy with company number and VAT number 11488280964. **The Netherlands:** MSIM Fund Management (Ireland) Limited, Rembrandt Tower, 11th Floor Amstelplein 1 1096HA, Netherlands. Telephone: 31 2-0462-1300. Morgan Stanley Investment Management is a branch office of MSIM Fund Management (Ireland) Limited. MSIM Fund Management (Ireland) Limited is regulated by the Central Bank of Ireland. **France:** MSIM Fund Management (Ireland) Limited, Paris Branch is a branch of MSIM Fund Management (Ireland) Limited, a company registered in Ireland, regulated by the Central Bank of Ireland and whose registered office is at The Observatory, 7-11 Sir John Rogerson's Quay, Dublin 2, D02 VC42, Ireland. MSIM Fund Management (Ireland) Limited Paris Branch with seat at 61 rue de Monceau 75008 Paris, France, is registered in France with company number 890 071 863 RCS. **Spain:** MSIM Fund Management (Ireland) Limited, Sucursal en España is a branch of MSIM Fund Management (Ireland) Limited, a company registered in Ireland, regulated by the Central Bank of Ireland and whose registered office is at The Observatory, 7-11 Sir John Rogerson's Quay, Dublin 2, D02 VC42, Ireland. MSIM Fund Management (Ireland) Limited, Sucursal en España with seat in Calle Serrano 55, 28006, Madrid, Spain, is registered in Spain with tax identification number W0058820B. **Switzerland:** Morgan Stanley & Co. International plc, London, Zurich Branch Authorised and regulated by the Eidgenössische Finanzmarktaufsicht ("FINMA"). Registered with the Register of Commerce Zurich CHE-115.415.770. Registered Office: Beethovenstrasse 33, 8002 Zurich, Switzerland, Telephone +41 (0) 44 588 1000. Facsimile Fax: +41(0) 44 588 1074.

**Australia:** This publication is disseminated in Australia by Morgan Stanley Investment Management (Australia) Pty Limited ACN: 122040037, AFSL No. 314182, which accepts responsibility for its contents. This publication, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. **Hong Kong:** This document has been issued by Morgan Stanley Asia Limited for use in Hong Kong and shall only be made available to "professional investors" as defined under the Securities and Futures Ordinance of Hong Kong (Cap 571). The contents of this document have not been reviewed nor approved by any regulatory authority including the Securities and Futures Commission in Hong Kong. Accordingly, save where an exemption is available under the relevant law, this document shall not be issued, circulated, distributed, directed at, or made available to, the public in Hong Kong. **Singapore:** This publication should not be considered to be the subject of an invitation for subscription or purchase, whether directly or indirectly, to the public or any member of the public in Singapore other than (i) to an institutional investor under section 304 of the Securities and Futures Act, Chapter 289 of Singapore ("SFA"), (ii) to a "relevant person" (which includes an accredited investor) pursuant to section 305 of the SFA, and such distribution is in accordance with the conditions specified in section 305 of the SFA; or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. In particular, for investment funds that are not authorized or recognized by the MAS, units in such funds are not allowed to be offered to the retail public; any written material issued to persons as aforementioned in connection with an offer is not a

prospectus as defined in the SFA and, accordingly, statutory liability under the SFA in relation to the content of prospectuses does not apply, and investors should consider carefully whether the investment is suitable for them. This publication has not been reviewed by the Monetary Authority of Singapore.

#### IMPORTANT INFORMATION

**EMEA: This marketing communication has been issued by MSIM Fund Management (Ireland) Limited. MSIM Fund Management (Ireland) Limited is regulated by the Central Bank of Ireland. MSIM Fund Management (Ireland) Limited is incorporated in Ireland as a private company limited by shares with company registration number 616661 and has its registered address at The Observatory, 7-11 Sir John Rogerson's Quay, Dublin 2, D02 VC42, Ireland.**

This document contains information relating to the sub-fund ("Fund") of Morgan Stanley Investment Funds, a Luxembourg domiciled Société d'Investissement à Capital Variable. Morgan Stanley Investment Funds (the "Company") is registered in the Grand Duchy of Luxembourg as an undertaking for collective investment pursuant to Part 1 of the Law of 17th December 2010, as amended. The Company is an Undertaking for Collective Investment in Transferable Securities ("UCITS").

Applications for shares in the Fund should not be made without first consulting the current Prospectus, Key Investor Information Document ("KIID"), Annual Report and Semi-Annual Report ("Offering Documents"), or other documents available in your local jurisdiction which is available free of charge from the Registered Office: European Bank and Business Centre, 6B route de Trèves, L-2633 Senningerberg, R.C.S. Luxembourg B 29 192. In addition, all Italian investors should refer to the 'Extended Application Form', and all Hong Kong investors should refer to the 'Additional Information for Hong Kong Investors' section, outlined within the Prospectus. Copies of the Prospectus, KIID, the Articles of Incorporation and the annual and semi-annual reports, in German, and further information can be obtained free of charge from the representative in Switzerland. The representative in Switzerland is Carnegie Fund Services S.A., 11, rue du Général-Dufour, 1204 Geneva. The paying agent in Switzerland is Banque Cantonale de Genève, 17, quai de l'Île, 1204 Geneva. The document has been prepared solely for informational purposes and does not constitute an offer or a recommendation to buy or sell any particular security or to adopt any specific investment strategy.

Any index referred to herein is the intellectual property (including registered trademarks) of the applicable licensor. Any product based on an index is in no way sponsored, endorsed, sold or promoted by the applicable licensor and it shall not have any liability with respect thereto.

The views and opinions expressed are those of the portfolio management team at the time of writing/of this presentation and are subject to change at any time due to market, economic, or other conditions, and may not necessarily come to pass. These comments are not representative of the opinions and views of the firm as a whole. Holdings, countries and sectors/ region weightings are subject to change daily. All information provided is for informational purposes only and should not be deemed as a recommendation to buy or sell securities in the sectors and regions referenced. Information regarding expected market returns and market outlook is

based on the research, analysis, and opinions of the team. These conclusions are speculative in nature, may not come to pass, and are not intended to predict the future of any specific Morgan Stanley Investment Management investment. Past performance is no guarantee of future results.

All investments involve risks, including the possible loss of principal. The material contained herein has not been based on a consideration of any individual client circumstances and is not investment advice, nor should it be construed in any way as tax, accounting, legal or regulatory advice. To that end, investors should seek independent legal and financial advice, including advice as to tax consequences, before making any investment decision.

**The information contained in this communication is not a research recommendation or 'investment research' and is classified as a 'Marketing Communication' in accordance with the applicable European or Swiss regulation. This means that this marketing communication (a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research (b) is not subject to any prohibition on dealing ahead of the dissemination of investment research.**

MSIM has not authorised financial intermediaries to use and to distribute this document, unless such use and distribution is made in accordance with applicable law and regulation. MSIM shall not be liable for, and accepts no liability for, the use or misuse of this document by any such financial intermediary. If you are a distributor of the Morgan Stanley Investment Funds, some or all of the funds or shares in individual funds may be available for distribution. Please refer to your sub-distribution agreement for these details before forwarding fund information to your clients.

The whole or any part of this work may not be reproduced, copied or transmitted or any of its contents disclosed to third parties without MSIM's express written consent.

All information contained herein is proprietary and is protected under copyright law.

This document may be translated into other languages. Where such a translation is made this English version remains definitive. If there are any discrepancies between the English version and any version of this document in another language, the English version shall prevail.